Hollow chitosan nanocomposite as drug carrier system for controlled delivery of ramipril

Basu, Tanushree; Pal, Bonamali; Singh, Satnam

doi:10.1016/j.cplett.2018.06.053

Cited by 16 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At higher pH, the swelling is quite limited and drug release is slightly slow. As reported in a similar study, the observation of sustained release for the same pH (up to 720 min) might be due to the interaction of amino group of CS with that of the carboxyl group of MMC [63].…”

Section: Drug Release Kinetics Based On Different Types Of Pharmacokinetics Modelssupporting

confidence: 73%

Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots–Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

Nanotechnology-based drug delivery systems are an emerging technology for the targeted delivery of chemotherapeutic agents in cancer therapy with low/no toxicity to the non-cancer cells. With that view, the present work reports the synthesis, characterization, and testing of Mn:ZnS quantum dots (QDs) conjugated chitosan (CS)-based nanocarrier system encapsulated with Mitomycin C (MMC) drug. This fabricated nanocarrier, MMC@CS-Mn:ZnS, has been tested thoroughly for the drug loading capacity, drug encapsulation efficiency, and release properties at a fixed wavelength (358 nm) using a UV–Vis spectrophotometer. Followed by the physicochemical characterization, the cumulative drug release profiling data of MMC@CS-Mn:ZnS nanocarrier (at pH of 6.5, 6.8, 7.2, and 7.5) were investigated to have the highest release of 56.48% at pH 6.8, followed by 50.22%, 30.88%, and 10.75% at pH 7.2, 6.5, and 7.5, respectively. Additionally, the drug release studies were fitted to five different pharmacokinetic models including pesudo-first-order, pseudo-second-order, Higuchi, Hixson–Crowell, and Korsmeyers–Peppas models. From the analysis, the cumulative MMC release suits the Higuchi model well, revealing the diffusion-controlled mechanism involving the correlation of cumulative drug release proportional to the function square root of time at equilibrium, with the correlation coefficient values (R2) of 0.9849, 0.9604, 0.9783, and 0.7989 for drug release at pH 6.5, 6.8, 7.2, and 7.5, respectively. Based on the overall results analysis, the formulated nanocarrier system of MMC synergistically envisages the efficient delivery of chemotherapeutic agents to the target cancerous sites, able to sustain it for a longer time, etc. Consequently, the developed nanocarrier system has the capacity to improve the drug loading efficacy in combating the reoccurrence and progression of cancer in non-muscle invasive bladder diseases.

show abstract

Section: Drug Release Kinetics Based On Different Types Of Pharmacokinetics Modelssupporting

confidence: 73%

Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots–Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In recent years, some drug carrier systems, such as lipidosome and nanoparticle drug carriers, can improve precise drug targeting and release at the corresponding sites, which can enhance the therapeutic effect of the drug and lead to a lower dose requirement and a reduction in side effects [34, 35]. Future studies should focus on effective delivery of MLPs to make their in vivo application possible.…”

Section: Discussionmentioning

confidence: 99%

Purification, characterization and in vitro and in vivo immune enhancement of polysaccharides from mulberry leaves

et al. 2019

View full text Add to dashboard Cite

Mulberry leaf polysaccharide (MLP) was extracted and purified by DEAE-52 cellulose and Sephadex G-100 column chromatography to afford two major purified polysaccharides (MLP-1 and MLP-2). The purified polysaccharides were characterized, and their immune-enhancing properties were investigated. MLP-1 had a molecular weight of 9.31×104 Da and was composed of mannose, rhamnose, glucose, galactose, xylose, and arabinose in a molar ratio of 0.71:1.00:2.76:1.13:3.70:2.81. The molecular weight of MLP-2 was 2.22×106 Da, and its monosaccharide constituents were mannose, rhamnose, glucose, galactose, and arabinose in a molar ratio of 1.31:8.45:6.94:1.00:11.96. Infrared spectroscopy showed that each MLP had a typical absorption peak characteristic of sugars, and ultraviolet (UV) spectroscopy showed that neither MLP contained nucleic acid or protein components. Then, the abilities of these polysaccharides to stimulate spleen lymphocyte proliferation in mice in vitro were compared by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. MLP-2 was more effective than MLP-1; therefore, MLP-2 was chosen for the study of its immune-enhancing effects in vivo. For the in vivo experiments, 14-day-old chickens immunized with Newcastle disease (ND) vaccine were orally administered MLP-2, and Astragalus polysaccharide (APS) was used as the control. Each chicken was orally administered 4 mg or 8 mg of MLP-2 for seven consecutive days starting three days before ND vaccine immunization. MLP-2 significantly improved the ND serum antibody titer and interleukin-2 (IL-2), interferon-γ (IFN-γ) and immunoglobulin A (sIgA) concentrations in tracheal and jejunal wash fluids, and increasing numbers of immune globulin A-positive (IgA+) cells in cecal tonsils and increased body weight. These results indicated that MLP-2 could significantly enhance immune activity and could therefore be utilized as an immunopotentiator drug candidate.

show abstract

“…This variation in release behaviour of BSA is attributed to swelling behaviour of Cs‐SiO 2 hollow NPs in acidic medium . Also, Basu et.al reported the pH dependent release of ramipril from hollow chitosan matrix . Du.…”

Section: Introductionmentioning

confidence: 94%

Fe₃O₄ @ PLGA‐PEG Nanocomposite for Improved Delivery of Methotrexate in Cancer Treatment

2018

Self Cite

View full text Add to dashboard Cite

Magnetic Fe 3 O 4 nanoparticles are gaining significance in drug delivery applications owing to their targeting capability. Surface modification of amphiphilic block polymers by Fe 3 O 4 nanoparticles increases their properties. In this study, Fe 3 O 4 @ PLGA-PEG nanocomposite is prepared by double emulsion (w/ o/w) method. A shift in the 2Θ values for the composite in XRD attributes to interaction between Fe 3 O 4 and PLGA-PEG. Also, a shift in the Fe-O band in the FTIR spectrum of Fe 3 O 4 @PLGA-PEG from 578 cm -1 to 510 cm -1 confirms the formation of nanocomposite. Surface morphology of the prepared nanocomposite is analyzed by TEM and AFM. Decrease in agglomeration due to electrostatic repulsion between the polymer chains and magnetic particles is observed while an increased surface area (61.0nm) confirms the formation of the nanocomposite. To determine the effectiveness of the prepared magnetically modified nanoparticles, methotrexate (anticancer drug) is encapsulated into the nanocomposite. High entrapment effi-ciency of 95% is observed when polymer:drug is 1:1. The invitro release profile shows that pH of release medium plays a significant role. At physiological pH of 7.3 there is only 15% methotrexate release while nearly 86% of methotrexate release is observed at acidic pH of 4.6 over 72h. Korsemeyer-Peppas model of drug release (R 2 -0.9868) represents swelling controlled release of methotrexate. Further, the cytotoxic cell viability assay on SK-BR-3 (breast adinocarcinoma) cells showed that methotrexate loaded onto the nanocomposite showed higher cell viability as compared to free methotrexate after 96h of incubation. The fluorescent cell imaging also showed that methotrexate released slowly from the nanoparticles and diffused into the nucleus without losing its cytotoxic effect on the cancer cells. Based on these properties of the magnetically modified PLGA-PEG nanoparticles they can be used as targeting drug delivery agents in treatment of cancer therapy.

show abstract

Hollow chitosan nanocomposite as drug carrier system for controlled delivery of ramipril

Cited by 16 publications

References 30 publications

Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots–Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer

Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots–Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer

Purification, characterization and in vitro and in vivo immune enhancement of polysaccharides from mulberry leaves

Fe₃O₄ @ PLGA‐PEG Nanocomposite for Improved Delivery of Methotrexate in Cancer Treatment

Contact Info

Product

Resources

About

Hollow chitosan nanocomposite as drug carrier system for controlled delivery of ramipril

Cited by 16 publications

References 30 publications

Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots–Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer

Drug Release Profiles of Mitomycin C Encapsulated Quantum Dots–Chitosan Nanocarrier System for the Possible Treatment of Non-Muscle Invasive Bladder Cancer

Purification, characterization and in vitro and in vivo immune enhancement of polysaccharides from mulberry leaves

Fe3O4 @ PLGA‐PEG Nanocomposite for Improved Delivery of Methotrexate in Cancer Treatment

Contact Info

Product

Resources

About

Fe₃O₄ @ PLGA‐PEG Nanocomposite for Improved Delivery of Methotrexate in Cancer Treatment